Extracellular Regulated Kinase 1/2 Signaling Is a Critical Regulator of Interleukin-1β-Mediated Astrocyte Tissue Inhibitor of Metalloproteinase-1 Expression

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Fields, Jerel ^a,b   Cisneros, Irma E ^a   Borgmann, Kathleen ^a   Ghorpade, Anuja ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CCAAT ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ASTROCYTE; CELL ISOLATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ASTROCYTES; BRAIN; BUTADIENES; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL NUCLEUS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1BETA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; NITRILES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSCRIPTION FACTOR AP-1;

EID: 84874005957     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056891     Document Type: Article

References (51)

1. Sofroniew MV, (2005) Reactive astrocytes in neural repair and protection. The Neuroscientist: a review journal bringing neurobiology, neurology and psychiatry 11: 400-407.
2. Sofroniew MV, (2009) Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 32: 638-647.
3. Sofroniew MV, Vinters HV, (2010) Astrocytes: biology and pathology. Acta Neuropathol 119: 7-35.
4. Boisse L, Gill MJ, Power C, (2008) HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin 26: 799-819 x.
5. Suryadevara R, Holter S, Borgmann K, Persidsky R, Labenz-Zink C, et al. (2003) Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: Links to HIV-1 dementia. Glia 44: 47-56.
6. Araque A, Sanzgiri RP, Parpura V, Haydon PG, (1999) Astrocyte-induced modulation of synaptic transmission. Can J Physiol Pharmacol 77: 699-706.
7. Arthur FW, Shivers RR, Bowman PD, (1987) Astrocyte-mediated induction of tight junctions in brain capillary endothelium: an efficient in vitro model. Dev Brain Res 36: 155-159.
8. Aschner M, (1998) Immune and inflammatory responses in the CNS: modulation by astrocytes. Toxicol Lett 102-103: 283-287.
9. Blumberg BM, Gelbard HA, Epstein LG, (1994) HIV-1 infection of the developing nervous system: central role of astrocytes in pathogenesis. Virus Res 32: 253-267.
10. Directors NAoSaTA (2009) African Women: NASTAD.
11. Gardner J, Ghorpade A, (2003) Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J Neurosci Res 74: 801-806.
12. Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL, (1998) Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol 152: 729-741.
13. Jaworski DM, (2000) Differential regulation of tissue inhibitor of metalloproteinase mRNA expression in response to intracranial injury. Glia 30: 199-208.
14. Hornebeck W, (2003) Down-regulation of tissue inhibitor of matrix metalloprotease-1 (TIMP-1) in aged human skin contributes to matrix degradation and impaired cell growth and survival. Pathol Biol (Paris) 51: 569-573.
15. Lambert E, Boudot C, Kadri Z, Soula-Rothhut M, Sowa ML, et al. (2003) Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J 372: 767-774.
16. Ould-yahoui A, Tremblay E, Sbai O, Ferhat L, Bernard A, et al. (2009) A new role for TIMP-1 in modulating neurite outgrowth and morphology of cortical neurons. PLoS One 4: e8289.
17. Bloomston M, Shafii A, Zervos EE, Rosemurgy AS, (2002) TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res 102: 39-44.
18. Ikenaka Y, Yoshiji H, Kuriyama S, Yoshii J, Noguchi R, et al. (2003) Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer 105: 340-346.
19. Itoh Y, Ito A, Iwata K, Tanzawa K, Mori Y, et al. (1998) Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface. J Biol Chem 273: 24360-24367.
20. Kettlun AM, Cartier L, Garcia L, Collados L, Vasquez F, et al. (2003) TIMPs and MMPs expression in CSF from patients with TSP/HAM. Life Sci 72: 2863-2876.
21. Stetler-Stevenson WG, (2008) Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 1: re6.
22. Dhar A, Gardner J, Borgmann K, Wu L, Ghorpade A, (2006) Novel role of TGF-beta in differential astrocyte-TIMP-1 regulation: implications for HIV-1-dementia and neuroinflammation. J Neurosci Res 83: 1271-1280.
23. Magnoni S, Baker A, Thomson S, Jordan G, George S, et al. (2007) Neuroprotective effect of adenoviral-mediated gene transfer of TIMP-1 and-2 in ischemic brain injury. Gene Ther 14: 621-625.
24. Bugno M, Witek B, Bereta J, Bereta M, Edwards DR, et al. (1999) Reprogramming of TIMP-1 and TIMP-3 expression profiles in brain microvascular endothelial cells and astrocytes in response to proinflammatory cytokines. FEBS Lett 448: 9-14.
25. Ashutosh, Chao C, Borgmann K, Brew K, Ghorpade A, (2012) Tissue inhibitor of metalloproteinases-1 protects human neurons from staurosporine and HIV-1-induced apoptosis: mechanisms and relevance to HIV-1-associated dementia. Cell Death Dis 3: e332.
26. Hall MC, Young DA, Waters JG, Rowan AD, Chantry A, et al. (2003) The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1. J Biol Chem 278: 10304-10313.
27. Young DA, Billingham O, Sampieri CL, Edwards DR, Clark IM, (2005) Differential effects of histone deacetylase inhibitors on phorbol ester- and TGF-beta1 induced murine tissue inhibitor of metalloproteinases-1 gene expression. The FEBS journal 272: 1912-1926.
28. Barter MJ, Pybus L, Litherland GJ, Rowan AD, Clark IM, et al. (2010) HDAC-mediated control of ERK- and PI3K-dependent TGF-beta-induced extracellular matrix-regulating genes. Matrix biology: journal of the International Society for Matrix Biology 29: 602-612.
29. Tong L, Smyth D, Kerr C, Catterall J, Richards CD, (2004) Mitogen-activated protein kinases Erk1/2 and p38 are required for maximal regulation of TIMP-1 by oncostatin M in murine fibroblasts. Cellular signalling 16: 1123-1132.
30. Li F, Curry TE Jr, (2009) Regulation and function of tissue inhibitor of metalloproteinase (TIMP) 1 and TIMP3 in periovulatory rat granulosa cells. Endocrinology 150: 3903-3912.
31. Rivera S, Tremblay E, Timsit S, Canals O, Ben-Ari Y, et al. (1997) Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response. J Neurosci 17: 4223-4235.
32. Wilczynska KM, Gopalan SM, Bugno M, Kasza A, Konik BS, et al. (2006) A novel mechanism of tissue inhibitor of metalloproteinases-1 activation by interleukin-1 in primary human astrocytes. J Biol Chem 281: 34955-34964.
33. Fields J, Gardner-Mercer J, Borgmann K, Clark I, Ghorpade A, (2011) CCAAT/enhancer binding protein beta expression is increased in the brain during HIV-1-infection and contributes to regulation of astrocyte tissue inhibitor of metalloproteinase-1. Journal of neurochemistry 118: 93-104.
34. Gardner J, Borgmann K, Deshpande MS, Dhar A, Wu L, et al. (2006) Potential mechanisms for astrocyte-TIMP-1 downregulation in chronic inflammatory diseases. J Neurosci Res 83: 1281-1292.
35. Kaul M, Garden GA, Lipton SA, (2001) Pathways to neuronal injury and apoptosis in HIV-1-associated dementia. Nature 410: 988-993.
36. Ferrari CC, Depino AM, Prada F, Muraro N, Campbell S, et al. (2004) Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. Am J Pathol 165: 1827-1837.
37. Ferrari CC, Pott Godoy MC, Tarelli R, Chertoff M, Depino AM, et al. (2006) Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol Dis 24: 183-193.
38. Rossi JL, Ralay Ranaivo H, Patel F, Chrzaszcz M, Venkatesan C, et al. (2011) Albumin causes increased myosin light chain kinase expression in astrocytes via p38 mitogen-activated protein kinase. Journal of Neuroscience Research 89: 852-861.
39. Li R, Reiser G, (2011) Phosphorylation of Ser45 and Ser59 of alphaB-crystallin and p38/extracellular regulated kinase activity determine alphaB-crystallin-mediated protection of rat brain astrocytes from C2-ceramide- and staurosporine-induced cell death. Journal of neurochemistry 118: 354-364.
40. Hsieh HL, Wang HH, Wu WB, Chu PJ, Yang CM, (2010) Transforming growth factor-beta1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF-kappaB pathways. Journal of neuroinflammation 7: 88.
41. Friday BB, Adjei AA, (2008) Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clinical cancer research: an official journal of the American Association for Cancer Research 14: 342-346.
42. Schmittgen TD, Livak KJ, (2008) Analyzing real-time PCR data by the comparative C(T) method. Nature protocols 3: 1101-1108.
43. Manthrope M, Fagnani R, Skaper SD, Varon S, (1986) An automated colorimetric microassay for neurotrophic factors. Dev Brain Res 25: 191-198.
44. Clark IM, Rowan AD, Edwards DR, Bech-Hansen T, Mann DA, et al. (1997) Transcriptional activity of the human tissue inhibitor of metalloproteinases 1 (TIMP-1) gene in fibroblasts involves elements in the promoter, exon 1 and intron 1. Biochem J 324 (Pt 2): 611-617.
45. Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF, (2002) Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp Neurol 178: 13-20.
46. Dou H, Morehead J, Bradley J, Gorantla S, Ellison B, et al. (2006) Neuropathologic and neuroinflammatory activities of HIV-1-infected human astrocytes in murine brain. Glia.
47. Neary JT, Kang Y, Shi YF, (2004) Signaling from nucleotide receptors to protein kinase cascades in astrocytes. Neurochemical research 29: 2037-2042.
48. Davies SP, Reddy H, Caivano M, Cohen P, (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
49. Shen F, Li N, Gade P, Kalvakolanu DV, Weibley T, et al. (2009) IL-17 receptor signaling inhibits C/EBPbeta by sequential phosphorylation of the regulatory 2 domain. Science signaling 2: ra8.
50. Chen X, Liu W, Wang J, Wang X, Yu Z, (2002) STAT1 and STAT3 mediate thrombin-induced expression of TIMP-1 in human glomerular mesangial cells. Kidney Int 61: 1377-1382.
51. Fu ZY, Lv JH, Ma CY, Yang DP, Wang T, (2011) Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-small ka, CyrillicB pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 65: 163-167.